Association of cytochrome P450 2E1 polymorphisms and head and neck squamous cell cancer

Toxicology Letters

Volumn 151, Issue 1, 2004, Pages 273-282

  Neuhaus, Thomas ^a   Ko, Yon Dschun ^a   Lorenzen, Katrin ^a   Fronhoffs, Stefan ^a   Harth, Volker ^b   Bröde, Peter ^c   Vetter, Hans ^a   Bolt, Hermann M ^c   Pesch, Beate ^a,b   Brüning, Thomas ^b,c  

^a UNIVERSITY OF BONN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Inst F Arbeitsphysiologie An U   (Germany)

Author keywords

CYP2E1; Head and neck cancer; Polymorphism

Indexed keywords

CYTOCHROME P450 2E1; PROTEIN P53;

ADULT; ARTICLE; CANCER RISK; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; FEMALE; GENE MUTATION; HEAD AND NECK CANCER; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA;

NICOTIANA TABACUM;

EID: 2942511502     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2003.09.017     Document Type: Article

References (61)

1. Agundez J.A., Rodriguez I., Olivera M., Ladero J.M., Garcia M.A., Ribera J.M., Benitez J. CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Age Ageing. 26:1997;147-151
2. Anwar W.A., Abdel-Rahman S.Z., El-Zein R.A., Mostafa H.M., Au W.W. Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis. 17:1996;1923-1929
3. Bolt H.M., Roos P.H., Thier R. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and industrial medicine. Int. Arch. Occup. Environ. Health. 76:2003;174-185
4. Boyle P., Zheng T., Macfarlane G.J., McGinn R., Maisonneuve P., LaVecchia C., Scully C. Recent advances in the etiology and epidemiology of head and neck cancer. Curr. Opin. Oncol. 2:1990;539-545
5. Carriere V., Berthou F., Baird S., Belloc C., Beaune P., de Waziers I. Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics. 6:1996;203-211
6. Fairbrother K.S., Grove J., de Waziers I., Steimel D.T., Day C.P., Crespi C.L., Daly A.K. Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics. 8:1998;543-552
7. Farker K., Lehmann M.H., Oelschlagel B., Haerting J., Hoffmann A., Janitzky V., Schubert J. Impact of CYP2E1 genotype in renal cell and urothelial cancer patients. Exp. Toxicol. Pathol. 50:1998;425-431
8. Garte S., Gaspari L., Alexandrie A.K., Ambrosone C., Autrup H., Autrup J.L., Baranova H., Bathum L., Benhamou S., Boffetta P., Bouchardy C., Breskvar K., Brockmoller J., Cascorbi I., Clapper M.L., Coutelle C., Daly A., Dell'Omo M., Dolzan V., Dresler C.M., Fryer A., Haugen A., Hein D.W., Hildesheim A., Hirvonen A., Hsieh L.L., Ingelman-Sundberg M., Kalina I., Kang D., Kihara M., Kiyohara C., Kremers P., Lazarus P., Le Marchand L., Lechner M.C., van Lieshout E.M., London S., Manni J.J., Maugard C.M., Morita S., Nazar-Stewart V., Noda K., Oda Y., Parl F.F., Pastorelli R., Persson I., Peters W.H., Rannug A., Rebbeck T., Risch A., Roelandt L., Romkes M., Ryberg D., Salagovic J., Schoket B., Seidegard J., Shields P.G., Sim E., Sinnet D., Strange R.C., Stucker I., Sugimura H., To-Figueras J., Vineis P., Yu M.C., Taioli E. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomarkers Prev. 10:2001;1239-1248
9. Guengerich F.P., Kim D.H., Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4:1991;168-179
10. Hayashi S., Watanabe J., Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J. Biochem. Tokyo. 110:1991;559-565
11. Hildesheim A., Anderson L.M., Chen C.J., Cheng Y.J., Brinton L.A., Daly A.K., Reed C.D., Chen I.H., Caporaso N.E., Hsu M.M., Chen J.Y., Idle J.R., Hoover R.N., Yang C.S., Chhabra S.K. CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J. Natl. Cancer Inst. 89:1997;1207-1212
12. Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Karjalainen A., Sorsa M., Vainio H. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics. 2:1992;259-263
13. Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Karjalainen A., Vainio H. The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis. 14:1993;85-88
14. Hori H., Kawano T., Endo M., Yuasa Y. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and human esophageal squamous cell carcinoma susceptibility. J. Clin. Gastroenterol. 25:1997;568-575
15. Hung H.C., Chuang J., Chien Y.C., Chern H.D., Chiang C.P., Kuo Y.S., Hildesheim A., Chen C.J. Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmental factors and risk of oral cancer. Cancer Epidemiol. Biomarkers Prev. 6:1997;901-905
16. Ingelman-Sundberg M., Johansson I., Persson I., Oscarson M., Hu Y., Bertilsson L., Dahl M.L., Sjoqvist F. Genetic polymorphism of cytochrome P450. Functional consequences and possible relationship to disease and alcohol toxicity. EXS. 71:1994;197-207
17. Jahnke V., Matthias C., Fryer A., Strange R. Glutathione S-transferase and cytochrome-P-450 polymorphism as risk factors for squamous cell carcinoma of the larynx. Am. J. Surg. 172:1996;671-673
18. Kato S., Shields P.G., Caporaso N.E., Hoover R.N., Trump B.F., Sugimura H., Weston A., Harris C.C. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res. 52:1992;6712-6715
19. Kato S., Shields P.G., Caporaso N.E., Sugimura H., Trivers G.E., Tucker M.A., Trump B.F., Weston A., Harris C.C. Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol. Biomarkers Prev. 3:1994;515-518
20. Kato S., Onda M., Matsukura N., Tokunaga A., Tajiri T., Kim D.Y., Tsuruta H., Matsuda N., Yamashita K., Shields P.G. Cytochrome P4502E1 (CYP2E1) genetic polymorphism in a case-control study of gastric cancer and liver disease. Pharmacogenetics. 5:1995;S141-S144. (special issue)
21. Kato S., Onda M., Matsukura N., Tokunaga A., Matsuda N., Yamashita K., Shields P.G. Genetic polymorphisms of the cancer related gene and Helicobacter pylori infection in Japanese gastric cancer patients. An age and gender matched case-control study. Cancer. 77:1996;1654-1661
22. Kato S., Onda M., Matsukura N., Tokunaga A., Matsuda N., Yamashita K., Shields P.G. Helicobacter pylori infection and genetic polymorphisms for cancer-related genes in gastric carcinogenesis. Biomed. Pharmacother. 51:1997;145-149
23. Kharasch E.D., Thummel K.E. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 79:1993;795-807
24. Kim J.W., Lee C.G., Park Y.G., Kim K.S., Kim I.K., Sohn Y.W., Min H.K., Lee J.M., Namkoong S.E. Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical carcinoma. Cancer. 88:2000;2082-2091
25. Kiss I., Sandor J., Pajkos G., Bogner B., Hegedus G., Ember I. Colorectal cancer risk in relation to genetic polymorphism of cytochrome P450 1A1, 2E1, and glutathione-S-transferase M1 enzymes. Anticancer Res. 20:2000;519-522
26. Ko Y., Abel J., Harth V., Broede P., Antony C., Donat S., Fischer H.P., Ortiz-Pallardo M.E., Thier R., Sachinidis A., Vetter H., Bolt H.M., Herberhold C., Bruning T. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res. 61:2001;4398-4404
27. Ladero J.M., Agundez J.A., Rodriguez-Lescure A., Diaz-Rubio M., Benitez J. RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma. Gut. 39:1996;330-333
28. Lechevrel M., Wild C.P. Absence of a differential induction of cytochrome P450 2E1 by different alcoholic beverages in rats: implications for the aetiology of human oesophageal cancer. Arch. Toxicol. 71:1997;690-695
29. London S.J., Daly A.K., Cooper J., Carpenter C.L., Navidi W.C., Ding L., Idle J.R. Lung cancer risk in relation to the CYP2E1 Rsa I genetic polymorphism among African-Americans and Caucasians in Los Angeles County. Pharmacogenetics. 6:1996;151-158
30. Lucas D., Menez C., Girre C., Berthou F., Bodenez P., Joannet I., Hispard E., Bardou L.G., Menez J.F. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics. 5:1995;298-304
31. Lucas D., Menez C., Floch F., Gourlaouen Y., Sparfel O., Joannet I., Bodenez P., Jezequel J., Gouerou H., Berthou F., Bardou L.G., Menez J.F. Cytochromes P4502E1 and P4501A1 genotypes and susceptibility to cirrhosis or upper aerodigestive tract cancer in alcoholic Caucasians. Alcohol Clin. Exp. Res. 20:1996;1033-1037
32. Marchand L.L., Sivaraman L., Pierce L., Seifried A., Lum A., Wilkens L.R., Lau A.F. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res. 58:1998;4858-4863
33. Marchand L.L., Wilkinson G.R., Wilkens L.R. Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol. Biomarkers Prev. 8:1999;495-500
34. Matthias C., Bockmuhl U., Jahnke V., Harries L.W., Wolf C.R., Jones P.W., Alldersea J., Worrall S.F., Hand P., Fryer A.A., Strange R.C. The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal and laryngeal carcinomas. Pharmacogenetics. 8:1998;1-6
35. Morita S., Yano M., Shiozaki H., Tsujinaka T., Ebisui C., Morimoto T., Kishibuti M., Fujita J., Ogawa A., Taniguchi M., Inoue M., Tamura S., Yamazaki K., Kikkawa N., Mizunoya S., Monden M. CYP1A1, CYP2E1 and GSTM1 polymorphisms are not associated with susceptibility to squamous-cell carcinoma of the esophagus. Int. J. Cancer. 71:1997;192-195
36. Murata M., Watanabe M., Yamanaka M., Kubota Y., Ito H., Nagao M., Katoh T., Kamataki T., Kawamura J., Yatani R., Shiraishi T. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett. 165:2001;171-177
37. Norton N., Williams N.M., Williams H.J., Spurlock G., Kirov G., Morris D.W., Hoogendoorn B., Owen M.J., O'Donovan M.C. Universal, robust, highly quantitative SNP allele frequency measurement in DNA pools. Hum. Genet. 110:2002;471-478
38. Novak R.F., Woodcroft K.J. The alcohol-inducible form of cytochrome P450 (CYP 2E1): role in toxicology and regulation of expression. Arch. Pharm. Res. 23:2000;267-282
39. Oyama T., Kawamoto T., Mizoue T., Sugio K., Kodama Y., Mitsudomi T., Yasumoto K. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res. 17:1997;583-587
40. Persson I., Johansson I., Bergling H., Dahl M.L., Seidegard J., Rylander R., Rannug A., Hogberg J., Sundberg M.I. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett. 319:1993;207-211
41. Powell H., Kitteringham N.R., Pirmohamed M., Smith D.A., Park B.K. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. Pharmacogenetics. 8:1998;411-421
42. Przygodzki R.M., Bennett W.P., Guinee D.G. Jr., Khan M.A., Freedman A., Shields P.G., Travis W.D., Jett J.R., Tazelaar H., Pairolero P., Tratsek V., Liotta L.A., Harris C.C., Caporaso N.E. p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer. Pharmacogenetics. 8:1998;503-511
43. Shields P.G., Ambrosone C.B., Graham S., Bowman E.D., Harrington A.M., Gillenwater K.A., Marshall J.R., Vena J.E., Laughlin R., Nemoto T., Freudenheim J.L. A cytochrome P4502E1 genetic polymorphism and tobacco smoking in breast cancer. Mol. Carcinog. 17:1996;144-150
44. Stephens E.A., Taylor J.A., Kaplan N., Yang C.H., Hsieh L.L., Lucier G.W., Bell D.A. Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics. 4:1994;185-192
45. Sugimura H., Hamada G.S., Suzuki I., Iwase T., Kiyokawa E., Kino I., Tsugane S. CYP1A1 and CYP2E1 polymorphism and lung cancer, case-control study in Rio de Janeiro, Brazil. Pharmacogenetics. 5:1995;S145-S148. (special issue)
46. Tan W., Song N., Wang G.Q., Liu Q., Tang H.J., Kadlubar F.F., Lin D.X. Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferases M1, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China. Cancer Epidemiol. Biomarkers Prev. 9:2000;551-556
47. Tanaka E., Terada M., Misawa S. Cytochrome P4502E1: its clinical and toxicological role. J. Clin. Pharm. Ther. 25:2000;165-175
48. Thier R., Lewalter J., Selinski S., Bolt H.M. Re-evaluation of the effect of smoking on the methylation of N-terminal valine in haemoglobin. Arch. Toxicol. 75:2001;270-273
49. Thier R., Lewalter J., Selinski S., Bolt H.M. Possible impact of human CYP2E1 polymorphisms on the metabolism of acrylonitrile. Toxicol. Lett. 128:2002;249-255
50. Tuyns A.J. Drinking sensibly. The search for a limit. Br. J. Addict. 83:1988;35-36
51. Uematsu F., Ikawa S., Kikuchi H., Sagami I., Kanamaru R., Abe T., Satoh K., Motomiya M., Watanabe M. Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics. 4:1994;58-63
52. Watanabe J., Yang J.P., Eguchi H., Hayashi S., Imai K., Nakachi K., Kawajiri K. An Rsa I polymorphism in the CYP2E1 gene does not affect lung cancer risk in a Japanese population. Jpn. J. Cancer Res. 86:1995;245-248
53. Weber A., Bellmann U., Bootz F., Wittekind C., Tannapfel A. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck. Virchows Arch. 441:2002;133-142
54. Whysner J., Conaway C.C., Verna L., Williams G.M. Vinyl chloride mechanistic data and risk assessment: DNA reactivity and cross-species quantitative risk extrapolation. Pharmacol. Ther. 71:1996;7-28
55. Wong N.A., Rae F., Simpson K.J., Murray G.D., Harrison D.J. Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol. Pathol. 53:2000;88-93
56. Wong R.H., Du C.L., Wang J.D., Chan C.C., Luo J.C., Cheng T.J. XRCC1 and CYP2E1 polymorphisms as susceptibility factors of plasma mutant p53 protein and anti-p53 antibody expression in vinyl chloride monomer-exposed polyvinyl chloride workers. Cancer Epidemiol. Biomarkers Prev. 11:2002;475-482
57. Wu X., Shi H., Jiang H., Kemp B., Hong W.K., Delclos G.L., Spitz M.R. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis. 18:1997;967-973
58. Wu X., Amos C.I., Kemp B.L., Shi H., Jiang H., Wan Y., Spitz M.R. Cytochrome P450 2E1 DraI polymorphisms in lung cancer in minority populations. Cancer Epidemiol. Biomarkers Prev. 7:1998;13-18
59. Wynder E.L., Stellman S.D. Comparative epidemiology of tobacco-related cancers. Cancer Res. 37:1977;4608-4622
60. Yang C.S., Yoo J.S., Ishizaki H., Hong J.Y. Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanisms of regulation. Drug Metab. Rev. 22:1990;147-159
61. Yu M.W., Gladek-Yarborough A., Chiamprasert S., Santella R.M., Liaw Y.F., Chen C.J. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology. 109:1995;1266-1273